Brilinta's North America Anomaly Stymies AstraZeneca, Worries Analysts

Despite ticagrelor's resounding victory over Plavix in the global PLATO study, a subanalysis showing the antiplatelet drug didn't work on North Americans raises questions about how FDA will see the data.